GBA's "2021 Stock Phantasma"

1. Fortive
Let's start with Fortive. The underperformance of this stock is somewhat surprising, as its mix of industrial business gives it cyclical exposure to the improving economy. Moreover, management already hiked full-year adjusted diluted EPS guidance from the range of $2.40-$2.55 given in February to $2.50-$2.60 in April.

Perhaps one reason for the underperformance is because Fortive isn't the easiest company to understand. Around 40% of its revenue comes from its intelligent operating solutions (IOS) segment; the largest business within it is electronic test and measurement company Fluke. As such, the IOS is a play on the growth of automation and digitization and the need to ensure safety and reliability -- not least to meet regulatory requirements in the industrial economy.

Precision technologies (PT) generates 35% of revenue and makes products that help engineers develop new electrical and electronic products. Key customers read like a who's who of the major industrial companies, including GE,Siemens,Apple,Samsung, and Lockheed Martin. Management sees a growth opportunity from its customers developing internet of things (IoT) and automation solutions. Finally, advanced healthcare solutions (AHS) helps hospitals deliver healthcare. Its largest business is an infection prevention business, ASP.

Fortive has powerful tailwinds behind it. The collection of business that CEO Jim Lico has built up over the years generates a 58% gross profit margin and 23% profit margin while converting 18% of revenue into free cash flow (FCF). Lico believes a combination of mid-single-digit percentage revenue growth and margin expansion could lead to $1.6 billion in free cash flow (FCF) in five years -- equivalent to around 6.8% of the company's market cap.
 
We Gave this one out yesterday to everyone.

--
Bio Idea*

Verve Therapeutics initiated with a Buy at Guggenheim 07:01 VERV Guggenheim analyst Etzer Darout initiated coverage of Verve Therapeutics with a Buy rating and $84 price target.

Verve Therapeutics initiated with an Outperform at William Blair 07:00 VERV William Blair analyst Raju Prasad initiated coverage of Verve Therapeutics with an Outperform rating and $92 fair value estimate. Verve is developing one-time medicines for the treatment of cardiovascular diseases that have the potential to disrupt the current chronic care model, Prasad tells investors in a research note. The analyst says the company has generated "compelling" preclinical data in nonhuman primates with over 60% whole liver editing resulting in near-complete reductions in serum PCSK9 or ANGPTL3 protein levels and "impressive" lowering of LDL-C and triglycerides.

Verve Therapeutics, Inc. (VERV)

$52.27+4.07 (+8.44%)<-----------:thumbsup:
As of 9:37AM EDT.
 
Boy Jimbo got all tied up this morning on CNBC... started talking about CPR and then wanted to make a Covid joke and started to say I know no one wants to do CPR.. and caught himself half way through.... I could hear is earpiece from my bedroom SHUT UP!!!!!!
 
Van-

I have a rep at the Hedge Fund of selling winners too much. Usually after $10 per share gain I get antsy. This is a fault of mine. I just believe in constantly booking profits, that's how you make yearly money, if you hold everything and the market dives into end of year, you have worked a whole year, every day for NOTHING> Of course a HF can afford to do that but an average guy in his underwear... not so easy.

Ok MIME vs AGFY... if you sold one which one-?

MIME is just going up because of the hacking and ransomware. That looks like it's going to be an ongoing theme.

AGFY had some competition IPO poorly..... maybe a warning sign But they are on record raising guidance alot and last week-- PR

Agrify, Curaleaf enter into multi-year vertical farming R&D partnership 07/06 AGFY, CURLF Agrify Corporation (AGFY) announced that it has signed a definitive Collaboration Agreement forming a long-term research and development partnership with Curaleaf Holdings, Inc. (CURLF). The research will be focused on evaluating the impact of certain environmental conditions created and controlled by Agrify's Vertical Farming Units and Agrify Insights software platform on harvest yields, plant terpene profiles, and flavonoid concentrations. It will also explore and analyze techniques to enhance the aesthetic appeal, aroma, and overall chemical profile of cannabis flower. In addition, the joint research team plans to study the effect of regulated environments on the overall health and longevity of cannabis plants, including research on the maturation of the chemical profile of the plants over their lifecycle. Under the terms of the Agreement, Agrify will supply its VFUs and provide use of the Company's Agrify Insights software platform for a period of three years at Curaleaf's primary R&D facility located in Massachusetts, with an option to extend another three years. The collaboration combines Agrify's technology and expertise in creating optimized cultivation environments with Agrify Insights(TM)-based data and Curaleaf's expertise in cultivation and production of quality cannabis products. All test data collected by Agrify Insights will be jointly owned.
 
Hey Van did you know Japanese company is involved with ABB on those mini nuclear reactors.-!
They're everywhere... these Japanese companies...

Fluor says IHI is investing $20M in NuScale Power 05/26 FLR Fluor announced that IHI Corporation of Japan is investing $20M into NuScale Power, a small modular nuclear reactor technology company in which Fluor is the majority investor. IHI's immediate investment of $20M may be followed by another $20M later, the company said. In addition to IHI's ownership interest, IHI will become a manufacturing partner and have the opportunity to provide design services and heavy manufacturing of the steel plate reinforced concrete wall structures for NuScale SMR projects in which Fluor has the lead role, it added.

NuScale Power SPAC-?
 
You must log in or register to reply here.
Back
Top